Literature DB >> 24335972

Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Vicente E Torres1, Peter C Harris.   

Abstract

Polycystic kidney disease (PKD) is a leading cause of ESRD worldwide. In PKD, excessive cell proliferation and fluid secretion, pathogenic interactions of mutated epithelial cells with an abnormal extracellular matrix and alternatively activated interstitial macrophages, and the disruption of mechanisms controlling tubular diameter contribute to cyst formation. Studies with animal models suggest that several diverse pathophysiologic mechanisms, including dysregulation of intracellular calcium levels and cAMP signaling, mediate these cystogenic mechanisms. This article reviews the evidence implicating calcium and cAMP as central players in a network of signaling pathways underlying the pathogenesis of PKD and considers the therapeutic relevance of treatment strategies targeting cAMP signaling.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24335972      PMCID: PMC3871779          DOI: 10.1681/ASN.2013040398

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  165 in total

1.  Increased water intake decreases progression of polycystic kidney disease in the PCK rat.

Authors:  Shizuko Nagao; Kazuhiro Nishii; Makoto Katsuyama; Hiroki Kurahashi; Tohru Marunouchi; Hisahide Takahashi; Darren P Wallace
Journal:  J Am Soc Nephrol       Date:  2006-06-28       Impact factor: 10.121

2.  Renal epithelial cyst formation and enlargement in vitro: dependence on cAMP.

Authors:  R Mangoo-Karim; M Uchic; C Lechene; J J Grantham
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

3.  Local activation of protein kinase A inhibits morphogenetic movements during Xenopus gastrulation.

Authors:  Byung-Ho Song; Sun-Cheol Choi; Jin-Kwan Han
Journal:  Dev Dyn       Date:  2003-05       Impact factor: 3.780

4.  Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Authors:  Maria V Irazabal; Vicente E Torres; Marie C Hogan; James Glockner; Bernard F King; Troy G Ofstie; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  Kidney Int       Date:  2011-05-04       Impact factor: 10.612

5.  PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice.

Authors:  Ali K Ahrabi; Sara Terryn; Giovanna Valenti; Nathalie Caron; Claudine Serradeil-Le Gal; Danielle Raufaste; Soren Nielsen; Shigeo Horie; Jean-Marc Verbavatz; Olivier Devuyst
Journal:  J Am Soc Nephrol       Date:  2007-05-02       Impact factor: 10.121

6.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

7.  ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice.

Authors:  Carlo Spirli; Stefano Okolicsanyi; Romina Fiorotto; Luca Fabris; Massimiliano Cadamuro; Silvia Lecchi; Xin Tian; Stefan Somlo; Mario Strazzabosco
Journal:  Gastroenterology       Date:  2009-09-18       Impact factor: 22.682

8.  Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease.

Authors:  D A O'Sullivan; V E Torres; P A Gabow; S N Thibodeau; B F King; E J Bergstralh
Journal:  Am J Kidney Dis       Date:  1998-12       Impact factor: 8.860

9.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

Authors:  Loes van Keimpema; Frederik Nevens; Ragna Vanslembrouck; Martijn G H van Oijen; Aswin L Hoffmann; Helena M Dekker; Robert A de Man; Joost P H Drenth
Journal:  Gastroenterology       Date:  2009-07-29       Impact factor: 22.682

Review 10.  Anti-tumour strategies aiming to target tumour-associated macrophages.

Authors:  Xiaoqiang Tang; Chunfen Mo; Yongsheng Wang; Dandan Wei; Hengyi Xiao
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

View more
  114 in total

1.  Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2-Dependent Mechanism in Polycystic Kidney Disease.

Authors:  Nidhi Dwivedi; Shixin Tao; Abeda Jamadar; Sonali Sinha; Christianna Howard; Darren P Wallace; Timothy A Fields; Andrew Leask; James P Calvet; Reena Rao
Journal:  J Am Soc Nephrol       Date:  2020-06-17       Impact factor: 10.121

2.  The Polycystin-1, Lipoxygenase, and α-Toxin Domain Regulates Polycystin-1 Trafficking.

Authors:  Yaoxian Xu; Andrew J Streets; Andrea M Hounslow; Uyen Tran; Frederic Jean-Alphonse; Andrew J Needham; Jean-Pierre Vilardaga; Oliver Wessely; Michael P Williamson; Albert C M Ong
Journal:  J Am Soc Nephrol       Date:  2015-08-26       Impact factor: 10.121

Review 3.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

4.  Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Authors:  Vicente E Torres; Eiji Higashihara; Olivier Devuyst; Arlene B Chapman; Ronald T Gansevoort; Jared J Grantham; Ronald D Perrone; John Ouyang; Jaime D Blais; Frank S Czerwiec
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-23       Impact factor: 8.237

5.  Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor γ agonists.

Authors:  Stephanie M Flaig; Vincent H Gattone; Bonnie L Blazer-Yost
Journal:  J Transl Int Med       Date:  2016-09-23

Review 6.  G-Protein-Coupled Receptor Signaling in Cilia.

Authors:  Kirk Mykytyn; Candice Askwith
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-09-01       Impact factor: 10.005

Review 7.  Therapeutic Targets in Polycystic Liver Disease.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

8.  AC6 is the major adenylate cyclase forming a diarrheagenic protein complex with cystic fibrosis transmembrane conductance regulator in cholera.

Authors:  Andrew Thomas; Yashaswini Ramananda; KyuShik Mun; Anjaparavanda P Naren; Kavisha Arora
Journal:  J Biol Chem       Date:  2018-06-14       Impact factor: 5.157

9.  A cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease.

Authors:  Vijayakumar R Kakade; Shixin Tao; Madhumitha Rajagopal; Xia Zhou; Xiaogang Li; Alan S L Yu; James P Calvet; Pankaj Pandey; Reena Rao
Journal:  J Mol Cell Biol       Date:  2016-05-04       Impact factor: 6.216

10.  Phosphodiesterase Isoform Regulation of Cell Proliferation and Fluid Secretion in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Cibele S Pinto; Archana Raman; Gail A Reif; Brenda S Magenheimer; Corey White; James P Calvet; Darren P Wallace
Journal:  J Am Soc Nephrol       Date:  2015-08-19       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.